Previous Article | Next Article ![]()
Journal of Clinical Microbiology, December 1998, p. 3686-3688, Vol. 36, No. 12
Department of Medicine, Indiana University
School of Medicine, Indianapolis, Indiana 46202
Received 4 June 1998/Returned for modification 23 July
1998/Accepted 3 September 1998
Previous epidemiological studies of Chlamydia
trachomatis frequently have required expansion of isolates in
tissue culture. The possibility that C. trachomatis omp1
might undergo mutation during such expansion has not been examined
systematically. We found no differences in the omp1
sequences from 10 clinical specimens before and after 20 in vitro passages.
The omp1 gene of
Chlamydia trachomatis encodes the major outer membrane
protein (MOMP), an immunogenic surface protein containing serotype-specific epitopes (1, 4-6, 10, 20-23). MOMP
appears to be the most variable genetic marker for C. trachomatis, making omp1 genotyping a useful
epidemiologic tool. Several laboratories have observed omp1
sequence variation within serovars (2, 7, 9, 11, 18). It has
been suggested that such variation reflects adaptation in response to
host immune selection, allowing organisms to evade host immune defenses
(2, 14).
While clinical diagnosis of chlamydial infection no longer requires
expansion of organisms in vitro, experimental procedures frequently do,
in order to provide sufficient quantities of organisms for
neutralization assays, antibiotic susceptibility testing, and
examination of growth rates, etc. For these reasons, it is important to
know the frequency with which in vitro mutations that could affect
phenotype might occur. Moreover, the possibility that some of the
previously observed mutations in omp1 might have occurred
during in vitro growth has not been examined systematically. There is
precedent indicating the need for such an analysis. Differences in the
omp1 nucleotide sequences of the reference strains E/Bour (8, 15) and B/TW5/OT (12, 17) have been reported.
Since the isolates of origin were presumably the same, the possibility arises that in these cases MOMP might have undergone mutation during
unrestricted in vitro growth. To test this hypothesis, we obtained the
omp1 sequences from 10 clinical specimens containing C. trachomatis and compared them to the sequences of
omp1 from these 10 isolates after 20 in vitro passages.
Two isolates each of the five most prevalent serovars in our
population
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Effect of Serial Passage in Tissue Culture on
Sequence of omp1 from Chlamydia trachomatis
Clinical Isolates
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
D, E, F, I, and J
were chosen (Table
1) from clinical urogenital specimens
from which C. trachomatis previously had been isolated and
immunotyped (19). All specimens consisted of the original
transport medium into which a swab specimen had been inoculated and
which had been maintained at
70°C. Each specimen was split into two
aliquots. One aliquot was used for sequencing, and the other was used
for expansion in vitro, as previously described (13).
Seventy-two hours postinoculation, one vial from the passage of each
isolate was reimmunotyped by fluorescent-antibody staining with
serovar-specific monoclonal antibodies (19). The remaining vials were further passaged, as previously described (13).
At passages 5 and 10, vials for each isolate were again stained with serovar-specific monoclonal antibodies to verify the integrity of the
passage. There was insufficient volume in original specimen 115718 for
sequencing and expansion. Therefore, the initial in vitro expansion was
used as the "original" sample for sequencing. All isolates were
grown for 20 passages with the exception of isolate 115644, which
failed to grow after the sixth in vitro passage. DNA extraction was
done as previously described (18).
TABLE 1.
Isolates used in this study and consecutively passaged 20 times in vitro
PCR was done with the following primers specific to the C. trachomatis MOMP: MOMP-108 (5'-GGC CAT TAA TTG CTA CAG GAC ATC TTG TC-3'), located 108 bp upstream of the ATG initiator, and RVS-END (5'-AAG YCG AGC CCA GAA AYA CGG ATA GTG-3'), located about 80 bp downstream of the terminal TAA. One negative control reaction was run for every seven experimental reactions. DNA amplification was done in duplicate with PCR Core Kit Plus uracil-DNA-glycosylase (Boehringer Mannheim, Indianapolis, Ind.), as previously described (18). Nested reamplifications were required for the original clinical specimens due to the low yield of chlamydial DNA in these samples (18). Negative controls from the first round of amplification were also used as templates in the nested reamplifications of negative controls. Replicate PCR mixtures were pooled for sequencing. Automated sequencing was performed by Merlin Core Services (Vista, Calif.). The sequence of omp1 was determined for each original specimen and for each isolate after 20 in vitro passages. Sequences were aligned manually by using the program ESEE (3).
omp1 from all 10 specimens was successfully amplified by nested reamplification with the original specimen as the template. The resulting PCR product was approximately 1,050 bp (18). Full-length PCR products for omp1 were obtained from all isolates after expansion in cell culture with the exception of 115644. Sequencing results are summarized in Fig. 1. Where sequence was obtained for both the original specimen and the expanded isolate, sequences were identical. Several strains exhibited variation compared to published prototypes (Fig. 1). Although isolate 115644 could not be expanded in cell culture, the omp1 sequence of the original specimen and the omp1 sequences of the other serovar E isolate, 117424, were identical to that of E/Bour reported by Peterson et al. (15) and confirmed by us (18). This differs from the E/Bour sequence reported by Dean and Millman (8) by 10 nucleotides and four amino acids.
|
The nucleotide sequences for B/TW5/OT (12, 17) and E/Bour (8, 15) omp1 have been reported twice. The two B/TW5/OT sequences differ by five synonymous substitutions, four of which occur in conserved region 1. The two E/Bour sequences differ from each other in conserved regions of omp1 by 10 nucleotides and four amino acids. We also have sequenced our stock of E/Bour, which we have had since 1993, and found it to be identical to that reported by Peterson et al. (15). Since in each case the strains are purported to be from different stocks of the same isolate, one difference between them may be the time grown in vitro. Therefore, it is legitimate to suggest that prolonged expansion in cell culture could have led to the reported differences in omp1.
Alternatively, as these two strains were identified and classified at a time when immunotyping was the only means of classification, it is possible that they are not from the same stock but represent two different strains of the same serovar. Indeed, the data presented here suggest that serial passage in cell culture does not induce mutations in omp1 with any frequency under normal in vitro conditions. Consequently, it is reasonable to assume that omp1 sequences derived from expanded clinical specimens accurately represent the sequences of the organisms recovered from the infected person. However, this study does not address the extent to which variation might arise during in vivo passage (natural infection). There are multiple factors in natural infections, including the effect of the host immune response on MOMP, which are not duplicated in tissue culture but which could induce changes in the gene coding for this protein.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grant AI-31494 to R.B.J. from the National Institute for Allergy and Infectious Diseases, National Institutes of Health.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medicine, Infectious Diseases, Indiana University School of Medicine, 435 Emerson Hall, 545 Barnhill Dr., Indianapolis, IN 46202. Phone: (317) 278-1791. Fax: (317) 274-1587. E-mail: dstothar{at}iupui.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Baehr, W.,
Y.-X. Zhang,
T. Joseph,
H. Su,
F. E. Nano,
K. D. E. Everett, and H. D. Caldwell.
1988.
Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes.
Proc. Natl. Acad. Sci. USA
85:4000-4004 |
| 2. | Brunham, R., C. Yang, I. Maclean, J. Kimani, G. Maitha, and F. Plummer. 1994. Chlamydia trachomatis from individuals in a sexually transmitted disease core group exhibit frequent sequence variation in the major outer membrane protein (omp1) gene. J. Clin. Investig. 94:458-462. |
| 3. |
Cabot, E. L., and A. T. Beckenbach.
1989.
Simultaneous editing of multiple nucleic acid and protein sequences with ESEE.
Comput. Appl. Biosci.
5:233-234 |
| 4. |
Caldwell, H. D.,
J. Kromhout, and J. Schachter.
1981.
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.
Infect. Immun.
31:1161-1176 |
| 5. |
Caldwell, H. D., and R. C. Judd.
1982.
Structural analysis of chlamydial major outer membrane proteins.
Infect. Immun.
38:960-968 |
| 6. |
Caldwell, H. D., and J. Schachter.
1982.
Antigenic analysis of the major outer membrane protein of Chlamydia spp.
Infect. Immun.
35:1024-1031 |
| 7. | Dean, D., E. Oudens, G. Bolan, N. Padian, and J. Schachter. 1995. Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco. J. Infect. Dis. 172:1013-1022[Medline]. |
| 8. | Dean, D., and K. Millman. 1997. Molecular and mutation trends analyses of omp1 alleles for serovar E of Chlamydia trachomatis. J. Clin. Investig. 99:475-483[Medline]. |
| 9. | Frost, E. H., S. Deslandes, D. Gendron, D. Bourgaux-Ramoisy, and P. Bopurgaux. 1995. Variation outside variable segments of the major outer membrane protein distinguishes trachoma from urogenital isolates of the same serovar of Chlamydia trachomatis. Genitourin. Med. 71:18-23[Medline]. |
| 10. |
Hatch, T. P.,
D. W. Vance, and E. Al-Hossainy.
1981.
Identification of a major envelope protein in Chlamydia spp.
J. Bacteriol.
146:426-429 |
| 11. | Hayes, L. J., S. Pecharatana, R. L. Bailey, T. J. Hampton, M. A. Pickett, D. C. W. Mabey, P. J. Watt, and M. E. Ward. 1995. Extent and kinetics of genetic change in the omp1 gene of Chlamydia trachomatis in two villages with endemic trachoma. J. Infect. Dis. 172:268-272[Medline]. |
| 12. |
Hayes, L. J.,
M. A. Pickett,
J. W. Conlan,
S. Ferris,
J. S. Everson,
M. E. Ward, and I. N. Clark.
1990.
The major outer membrane proteins of Chlamydia trachomatis serovars A and B: intra-serovar amino acid changes do not alter specificities of serovar- and C subspecies-reactive antibody-binding domains.
J. Gen. Microbiol.
136:1559-1566 |
| 13. |
Jones, R. B.,
B. Van Der Pol, and B. P. Katz.
1989.
Effect of differences in specimen processing and passage technique on recovery of Chlamydia trachomatis.
J. Clin. Microbiol.
27:894-898 |
| 14. | Lampe, M. F., K. G. Wong, L. M. Kuehl, and W. E. Stamm. 1997. Chlamydia trachomatis major outer membrane protein variants escape neutralization by both monoclonal antibodies and human immune sera. Infect. Immun. 65:317-319[Abstract]. |
| 15. |
Peterson, E. M.,
B. A. Markoff, and L. M. de la Maza.
1990.
The major outer membrane protein nucleotide sequence of Chlamydia trachomatis, serovar E.
Nucleic Acids Res.
18:3414 |
| 16. | Sayada, C., E. Denamur, and J. Elion. 1992. Complete sequence of the major outer membrane protein-encoding gene of Chlamydia trachomatis serovar Da*. Gene 120:129-130[Medline]. |
| 17. |
Stephens, R. S.,
R. Sanchez-Pescador,
E. A. Wagar,
C. Inouye, and M. S. Urdea.
1987.
Diversity of Chlamydia trachomatis major outer membrane protein genes.
J. Bacteriol.
169:3879-3885 |
| 18. |
Stothard, D. R.,
G. Boguslawski, and R. B. Jones.
1998.
Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants.
Infect. Immun.
66:3618-3625 |
| 19. | Van Der Pol, B., and R. B. Jones. 1992. Comparison of immunotyping of Chlamydia trachomatis by indirect fluorescent-antibody staining and radioimmunoassay J. Clin. Microbiol. 30:1014-1015. |
| 20. | Wang, S. P., C.-C. Kuo, R. C. Barnes, R. S. Stephens, and J. T. Grayston. 1985. Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J. Infect. Dis. 152:791-800[Medline]. |
| 21. | Wang, S. P., and J. T. Grayston. 1991. Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a. J. Infect. Dis. 163:403-405[Medline]. |
| 22. |
Yuan, Y.,
Y.-X. Zhang,
N. G. Watkins, and H. D. Caldwell.
1989.
Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars.
Infect. Immun.
57:1040-1049 |
| 23. | Zhang, Y.-X., S. Stewart, T. Joseph, H. R. Taylor, and H. D. Caldwell. 1987. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. J. Immunol. 138:575-581[Abstract]. |
| 24. |
Zhang, Y.-X.,
S. G. Morrison, and H. D. Caldwell.
1990.
The nucleotide sequence of the major outer membrane protein gene of Chlamydia trachomatis serovar F.
Nucleic Acids Res.
18:1061 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»